



RNS REACH

**Byotrol Plc
("Byotrol" or the "Company")**

Launch of CHEMGENE MEDLAB into human healthcare

Byotrol plc (AIM:BYOT), the specialist infection prevention and control company, is pleased to announce the launch into human healthcare of its next-generation surface disinfection chemistry, branded CHEMGENE MEDLAB.

The CHEMGENE brand, previously marketed by Medimark Scientific Ltd and acquired by Byotrol in 2018, enjoys a long-standing reputation as a trusted choice for disinfecting surfaces and equipment across emergency services, laboratories, and human health organisations.

This new formulation is designed for market-leading, broad-spectrum efficacy, low toxicity and regulatory approval across the UK and EU under the increasingly stringent biocidal regulations.

CHEMGENE MEDLAB Multi-Surface Disinfectants are very effective against bacteria, yeasts, fungi, and viruses, with specifically tailored efficacy against:

- The ESKAPE group of bacteria, targeted in healthcare environments for their multi-drug resistance, and virulence.
- Critical viruses, including Norovirus, Adenovirus, and the Vaccinia virus—the accepted surrogate for enveloped viruses such as Coronavirus, HIV, Hepatitis B & C, and Herpes Simplex virus.
- Emerging fungus *Candida auris*, known for its global health threat due to multi-drug resistance and ease of transmission within healthcare settings.

CHEMGENE MEDLAB Multi-Surface Disinfectants are supported by rigorous microbiological testing to the latest European efficacy test methodologies, including stringent medical standards that simulate high soil conditions akin to the presence of blood and other organic fluids during disinfection.

For detailed information about the forthcoming CHEMGENE MEDLAB Multi-Surface Disinfectants range and supporting product documentation please visit our commercial website, www.byotrol.com.

Vivan Pinto, CEO of Byotrol, states:

"The launch of Byotrol's new and improved CHEMGENE MEDLAB range is a huge step forward in our plans to future-proof our portfolio for EU and UK BPR regulatory approvals. It is the second big recent step for us in healthcare markets, following the successful launch of ANIGENE into animal health markets last year. We are very excited about its potential."

For further information contact:

Byotrol Plc

Vivan Pinto, Chief Executive Officer

+44 (0)1925 742 000

Chris Sedwell, Chief Financial Officer

finnCap Limited (Nominated Adviser and Broker)

+44 (0)20 7220 0500

Geoff Nash/George Dollemore – Corporate Finance

Nigel Birks/Harriet Ward – ECM

Flagstaff Strategic and Investor Communications

+44 (0)20 7129 1474

Tim Thompson/Andrea Seymour/Fergus Mellon

byotrol@flagstaffcomms.com

Notes to editors

Byotrol plc (BYOT.L), quoted on AIM, is a specialist infection prevention and control company, operating globally in the Healthcare, Industrial, Food and Consumer sectors, providing low toxicity products with a broad-based and targeted efficacy across all microbial classes; bacteria, viruses (including coronavirus), fungi, moulds, mycobacteria and algae.

Byotrol's products can be used stand-alone or as ingredients within existing products, where they can significantly improve their performance, especially in personal hygiene, domestic and industrial disinfection, odour control, food production and food management.

Byotrol develops and commercialises technologies that create easier, safer and cleaner lives for everyone.

For more investor information, go to byotrolplc.com